Statement: We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial.
Primary_evidence: INTERVENTION 1:    Breast Cancer Patients   Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
Secondary_evidence: INTERVENTION 1:    Pralatrexate   Study drug 190 mg/m^2 for 2 to 4 weeks.